Kaleido Biosciences initiated with a Buy at Goldman Sachs. Goldman Sachs analyst Terence Flynn started Kaleido Biosciences with a Buy rating and $20 price target. The analyst sees several pipeline catalysts over the next 18 months and projects KB174 has blockbuster potential in hepatic encephalopathy.
https://thefly.com/landingPageNews.php?id=2883477
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.